News & AnalysisInfectious Disease

Approval of Novel TB Drug Celebrated—With Restraint

Science  11 Jan 2013:
Vol. 339, Issue 6116, pp. 130
DOI: 10.1126/science.339.6116.130

You are currently viewing the summary.

View Full Text

Summary

The U.S. Food and Drug Administration approved the drug, bedaquiline, for only patients who have multidrug-resistant tuberculosis, which can require up to 2 years of treatment. It is the first new tuberculosis drug to be green-lighted in more than 40 years, but the celebration was tempered as sobering challenges face the drug's wide scale use.